Summary: Statins reduced negative emotional bias in people with depression. The findings suggest statins may provide protection against depression.
Statins have been hailed as a wonder drug; the cholesterol-lowering drugs have been prescribed to tens of millions of people since their approval in the late 1980s to prevent heart attack and stroke. But the drugs may yet have additional benefits, some research has hinted, including on mental health.
Now, a new study examines the influence of statins on emotional bias, a marker for risk of depression.
The study appears in Biological Psychiatry.
Researchers led by Amy Gillespie, Ph.D., at the University of Oxford, Oxford, UK, conducted the online observational study from April 2020 through February 2021, at the height of the SARS-CoV-2 pandemic, when global stress levels were elevated and the incidence of psychiatric disorders spiked.
Over 2,000 participants in the UK recorded information about their current psychiatric symptoms, medications, and other lifestyle factors. They also performed cognitive tasks meant to measure memory, reward, and emotion processing, which are linked to depression vulnerability.
One task required participants to identify the emotional expressions of faces, which displayed varying degrees of fear, happiness, sadness, disgust, anger, or fear.
The vast majority of subjects (84%) were not taking either medication, but a small group were taking only statins (4%), only a different class of anti-hypertension medication (6%), or both (5%).
Participants taking statins were less likely to recognize fearful or angry faces and more likely to report them as positive, indicating they had reduced negative emotional bias.
Dr. Gillespie said that they “found that taking a statin medication was associated with significantly lower levels of negative emotional bias when interpreting facial expressions; this was not seen with other medications, such as blood pressure medications.”
“We know that reducing negative emotional bias can be important for the treatment of depression,” said Dr. Gillespie.
“Our findings are important as they provide evidence that statins may provide protection against depression. Of particular note, we saw these results during the high-stress context of the COVID-19 pandemic. Our findings also provide the first potential psychological explanation of statins’ mental health benefits,” in that they seem to affect emotion processing.
It remains unclear exactly how statins could protect against mental illness, but one possibility is that they may work through anti-inflammatory mechanisms, which have also been implicated in depression.
John Krystal, MD, Editor of Biological Psychiatry, said of the work, “Statins are among the most commonly prescribed medications based on their ability to prevent heart attacks and strokes. These new data raise the possibility that some of their positive effects on health could be mediated by the effects of these drugs on the brain that promote emotional resilience.”
“Researchers should prioritize investigating the possible use of statins as a preventative intervention for depression. Before use in clinical practice, it is important that future research confirms the potential psychological benefits of statins through controlled, randomized clinical trials,” Dr. Gillespie concluded.
About this psychopharmacology research news
Author: Press Office
Contact: Press Office – Elsevier
Image: The image is in the public domain
Original Research: Open access.
“Associations between statin use and negative affective bias during COVID-19: an observational, longitudinal UK study investigating depression vulnerability” by Amy L. Gillespie et al. Biological Psychiatry
Associations between statin use and negative affective bias during COVID-19: an observational, longitudinal UK study investigating depression vulnerability
There is growing interest in the antidepressant potential of statins. We tested whether statin use is associated with cognitive markers previously found to indicate psychological vulnerability to depression, within the context of the COVID-19 pandemic.
Between April 2020 – February 2021, we conducted an observational online study of 2043 UK adults. Participants completed cognitive tasks assessing processes related to depression vulnerability, including affective bias and reward processing. We also measured working memory, medication use and current psychiatric symptoms. Using mixed ANCOVA and regression models, we compared participants on statins alone (n=81), anti-hypertensive medication alone (n=126), both medications (n=111), or neither medication (n=1725).
Statin use was associated with reduced recognition of angry and fearful faces (F(1)=9.19, p=0.002; F(1)=6.9, p=0.009) and with increased misclassification of these expressions as positive. Increased recognition of angry faces at baseline predicted increased levels of depression and anxiety ten months later (β=3.61, p=0.027; β=2.37, p=0.002). Statin use was also associated with reduced learning about stimuli associated with loss (F(1, 1418)=9.90, p=0.002). These indicators of reduced negative bias were not seen in participants taking anti-hypertensive medication alone, suggesting that they were related to statin use in particular rather than non-specific demographic factors. Additionally, we found no evidence of an association between statin use and impairment in working memory.
Statin use was associated with cognitive markers indicative of reduced psychological vulnerability to depression, supporting their potential use as a prophylactic treatment for depression.